White & Case Advises Jubilant Pharma on Debut US$300 Million High Yield Bond Offering | White & Case LLP International Law Firm, Global Law Practice
White & Case Advises Jubilant Pharma on Debut US$300 Million High Yield Bond Offering

White & Case Advises Jubilant Pharma on Debut US$300 Million High Yield Bond Offering

Global law firm White & Case LLP has advised Jubilant Pharma Limited on its debut offering of US$300 million 4.875 percent senior unsecured notes due 2021.

Jubilant Pharma is a global integrated pharmaceuticals group offering a wide range of products and services to global pharmaceutical customers and is a wholly-owned subsidiary of Jubilant Life Sciences Limited, which is listed on the Bombay Stock Exchange and the National Stock Exchange in India.

Citigroup Global Markets Singapore Pte. Ltd., Credit Suisse (Hong Kong) Limited, DBS Bank Ltd., The Hongkong and Shanghai Banking Corporation Limited and J.P. Morgan (S.E.A.) Limited acted as joint global coordinators, joint lead managers and joint bookrunners for the offering. The notes were issued pursuant to Regulation S under the US Securities Act and are listed on the Singapore Exchange Securities Trading Limited.

The White & Case team which advised on the transaction was led by partner Debashis Dey (Dubai) and included partners Nandan Nelivigi (New York), Kaya Proudian and Guan Feng Chen (both Singapore) with support from associates James Clarke, Sankalp Labroo (both Dubai), Hendy Handoko, Christina Lui and Berdine Geh (all Singapore).

Press contact
For more information please speak to your local media contact.